|
| Press Releases |
|
 |
|
| Friday, June 3, 2016 |
|
|
Eisai Inc. Enters Into Collaboration Agreement to Co-Promote Eisai's Anticancer Agent Lenvima in Combination with Evorolimus as Treatment for Advanced Renal Cell Carcinoma in the United States |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has entered into an agreement with Novartis Pharmaceuticals Corporation, a U.S. affiliate of Novartis AG, to collaborate on commercial and medical affairs activities for Eisai's in-house developed novel anticancer agent Lenvima and the anticancer agent everolimus in the United States. more info >> |
|
| Wednesday, June 1, 2016 |
|
|
AbbVie and Eisai Subsidiary EA Pharma Commence Co-promotion of Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA in the Field of Gastrointestinal Disease |
| AbbVie GK, Eisai Co., Ltd. and its subsidiary EA Pharma Co., Ltd., announced that EA Pharma and AbbVie will commence the co-promotion of fully human anti-TNF-alpha monoclonal antibody HUMIRA for indications in the field of gastrointestinal disease (ulcerative colitis, Crohn's disease, intestinal Behcet's disease) as of today. more info >> |
|
| Wednesday, May 25, 2016 |
|
|
Eisai to Launch In-House Developed Antiepileptic Drug Fycompa (Perampanel Hydrate) |
| Eisai Co., Ltd. announced today that it will launch its in-house-discovered antiepileptic drug (AED) Fycompa Tablets 2 mg and 4 mg (perampanel hydrate) as an adjunctive therapy for partial-onset seizures (including secondarily generalized seizures) or primary generalized tonic-clonic seizures in patients with epilepsy showing inadequate response to other AEDs in Japan on May 26, 2016. more info >> |
|
| Tuesday, May 24, 2016 |
|
|
Eisai to Present New Research on Oncology Products and Pipeline at 52nd Asco Annual Meeting |
| Eisai Co., Ltd. announced today that a series of abstracts highlighting new study results on Halaven and Lenvima will be presented during the 52nd Annual Meeting of the American Society of Clinical Oncology. more info >> |
|
| Monday, May 16, 2016 |
|
|
U.S. FDA Approves Additional Indication for Eisai's Anticancer Agent Lenvima in Combination with Everolimus as Treatment for Advanced Renal Cell Carcinoma |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an additional indication for Eisai's in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. more info >> |
|
| Thursday, April 14, 2016 |
|
|
Aricept Approved in the Philippines for New Indication as Treatment for Dementia with Lewy Bodies |
| Eisai Co., Ltd. announced today that its subsidiary in the Philippines, HI-Eisai Pharmaceutical Inc., has received approval for a new indication for the symptomatic treatment of dementia with Lewy bodies (DLB) for anti-Alzheimer's agent Aricept (donepezil hydrochloride) in the Philippines, and has commenced information provision activities. more info >> |
|
| Tuesday, April 5, 2016 |
|
|
Eisai Receives Positive CHMP Opinion on New Indicator for Anticancer Agent Halaven for Treatment of Advanced Liposarcoma |
| Eisai Co., Ltd. announced today that its European regional headquarters Eisai Europe Ltd. has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on anticancer agent Halaven (eribulin mesylate) for treatment of adult patients with unresectable liposarcomas. more info >> |
|
| Thursday, March 31, 2016 |
|
|
Eisai Transfer the Rights to Investigational Anticancer Agent E7777 for European, U.S and Certain Emerging Markets to Dr. Reddy's Laboratories |
| Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the exclusive worldwide development and marketing rights (excluding Japan and Asia) for its investigational anticancer agent E7777 to Dr. Reddy's Laboratories Ltd. more info >> |
|
| Wednesday, March 30, 2016 |
|
|
Eisai Co., Ltd. and Ajinomoto Co., Inc. Announce Establishment of Gastrointestinal Specialty Pharma EA Pharma Co., Ltd. |
| Eisai Co., Ltd. and Ajinomoto Co., Inc. announced today that based on the integration agreement signed and announced on October 15, 2015, the gastrointestinal specialty pharma EA Pharma Co., Ltd. will be established through the splitting off of a portion of Eisai's gastrointestinal disease treatment. more info >> |
|
|
Eisai's Notification Regarding Revision of Consolidated Financial Results Forecasts (IFRS) for the Fiscal Year Ending March 31, 2016 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that based on recent trends in business results, etc., the company has revised its full-year consolidated financial results forecasts for the fiscal year ending March 31, 2016 (April 1, 2015 to March 31, 2016) previously announced on February 2, 2016. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Euro Manganese Announces Upsize to Previously Announced Financing of up to C$11.2m (A$12.3m) including a Private Placement with Eric Sprott
Apr 1, 2025 22:39 HKT/SGT
|
|
|
Wuling Motors (00305.HK) Achieves a Surge of 115.6% in Net Profit Attributable to Shareholders for 2024
Apr 1, 2025 21:53 HKT/SGT
|
|
|
Baguio Green Group Announces 2024 Annual Results
Apr 1, 2025 20:19 HKT/SGT
|
|
|
analytica Vietnam 2025 Opens Tomorrow: The Leading Laboratory Exhibition Returns to Vietnam
Apr 1, 2025 20:01 HKT/SGT
|
|
|
Sunshine Insurance: Practicing 'Insurance for the People'
Apr 1, 2025 18:50 HKT/SGT
|
|
|
Hitachi's New Corporate Vision: Changing the World and Future with the Power of Knowledge
Apr 1, 2025 18:46 JST
|
|
|
Hitachi: Strengthening Our Analytical Business to Solve Social Issues with Our Core Technologies
Apr 1, 2025 18:38 JST
|
|
|
Quam Greater China Magnificent 7 Makes a Stunning Debut: Don't Miss the Next Wave of China Investment Opportunities
Apr 1, 2025 17:27 HKT/SGT
|
|
|
Hitachi: Completion of New Production Facility for Semiconductor Manufacturing Equipment in Kasado Area
Apr 1, 2025 17:52 JST
|
|
|
FOURTH PARADIGM ANNOUNCES 2024 ANNUAL RESULTS
Apr 1, 2025 16:51 HKT/SGT
|
|
|
NEC has developed technologies that enable a secure workflow for personalized cancer vaccines and has proven their capabilities
Apr 1, 2025 16:15 JST
|
|
|
Mitsubishi Motors Launches Miland Virtual Car Lifestyle App Service
Apr 1, 2025 14:59 JST
|
|
|
Mitsubishi Corporation: Development of R&D Hub "iPark Kobe" in Kobe Medical Industry City
Apr 1, 2025 14:16 JST
|
|
|
Eisai to Divest Rights for Pariet in China to Peak Pharma
Apr 1, 2025 13:15 JST
|
|
|
Everbright Grand China Assets Recorded Revenue of RMB 45.9 Million in 2024
Apr 1, 2025 12:25 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
